Updated:
Premier Biotech
Premier Biotech manufactures diagnostic devices for rapid drug testing in the healthcare sector. The company offers oral fluid and urine testing devices for...
Premier Biotech
Premier Biotech manufactures diagnostic devices for rapid drug testing in the healthcare sector. The company offers oral fluid and urine testing devices for drugs of abuse. Its products are used in workplace testing, criminal justice, health services, and clinical medication monitoring.
General information
Firm type
other
Location
Region
North America
Country
United States
City
Minneapolis
Corporate office
Minneapolis, MN, United States
Sector focus
Frequently asked questions
What is Premier Biotech's primary business?
Premier Biotech provides oral fluid drug testing from end to end. It manufactures the FDA-cleared Oral-Eze collection device, performs the screening and confirmation testing in its own high-complexity laboratory in Minneapolis, and delivers results through a proprietary software portal. The business serves corporate employers, government agencies, addiction treatment clinics, and criminal justice programs.
Does Premier Biotech sell its collection devices to other laboratories?
Yes. The Oral-Eze device is marketed to third-party laboratories, occupational health providers, and research organizations that want to perform oral fluid testing without developing their own hardware. This creates a parallel revenue stream where Premier Biotech earns device sales and licensing fees from facilities that compete with its own lab services.
What certifications does Premier Biotech hold for its laboratory?
The Minneapolis laboratory operates as a high-complexity testing facility under the Clinical Laboratory Improvement Amendments, holding CLIA certification and state-level licensure. It participates in proficiency testing programs required for regulated workplace drug testing and for clinical toxicology reporting to healthcare providers.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: